|
⚲
|
| Keyboard |
| Ally Bridge Group NY LLC
✚
|
|
|---|---|
| CRD # | 291072 |
| SEC # | 801-121984 |
| CIK # | 0001822947 |
| AUM | 218.9 M (2026-03-31) |
| Employees | 7 (57% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 646-829-9373 |
| Address | 430 Park Avenue New York, NY 10022 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($M) |
|---|
| Fees and Compensation — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
Item 5. Fees and Compensation Asset-Based and Performance-Based Compensation. The fee schedules for the Clients are described in detail in each Client’s Governing Documents. As a general matter, the Clients pay the Adviser or its affiliates an asset-based investment management fee each month in arrears ranging from 1.50% to 2.00% per annum based on the value of the net assets of the respective Client on the last day of the month (the "Management Fee"). The Adviser may waive or modify the Management Fee for investors that are members, principals, employees or affiliates of the Adviser, relatives of such persons, and for certain investors, in the Adviser’s sole discretion. The Adviser, or one of its affiliates serving as a general partner of a Client, is entitled to receive annual performance-based compensation of up to 20% (the “Incentive Allocation”) from the Clients, which is compensation that is based on a share of net capital appreciation of the assets of a Client. The Incentive Allocation is subject to a loss carryforward provision. The Adviser, or its applicable affiliate, may waive or modify the Incentive Allocation for investors that are members, principals, employees or affiliates of the Adviser, relatives of such persons, and for certain large or strategic investors. Expenses. In addition to bearing the Management Fee and Incentive Allocation, if any, the Clients are also subject to other expenses related to its investments and operations, such as (i) professional fees (including, without limitation, in respect of economic and other consultants and outside directors’ fees and expenses (such as travel, lodging and meals)) incurred in connection with investments, whether or not such investments are consummated, (including, without limitation, negotiation and due diligence costs and legal expenses incurred in connection with workouts involving underlying portfolio companies); (ii) expenses of purchasing, carrying and disposing of portfolio positions such as commissions, borrowing charges on securities sold short, interest on margin accounts and other indebtedness; (iii) prime brokerage fees; (iv) custodial fees; (v) litigation, indemnification and other extraordinary expenses, if any; (vi) legal, the cost of negotiating side letters, related governmental and regulatory fees including, without limitation: Forms 13D, 13F, 13G, 13H, Form PF, and AIFMD Annex IV and other filings and reports the preparation and submission of which currently or in the future may be required of a Client or the Adviser under applicable law, audit, tax, accounting, the administrator (including middle/back office and/or independent shadow accounting services) and anti-money laundering officer fees; (vii) market data, modeling, valuation services, order management systems, portfolio management systems, risk management systems and/or independent risk advisory services (including third-party software licensing, implementation, data management and recovery services); (viii) research, including third-party research and market data (excluding the cost of terminals or other computer hardware incorporated in the cost of obtaining such research and market data), and legal expenses; (ix) administration fees; (x) the Management Fee; (xi) clearing costs; (xii) exchange fees; (xiii) insurance costs, including, without limitation, errors and omissions insurance (subject to applicable law); (xiv) brokerage fees and bank charges; (xv) marketing and related travel expenses (including any representative fees and expenses); and (xvi) any other expenses related to the purchase, sale or transmittal of Client assets (including, without limitation, travel directly related to portfolio management, research or structuring of the Client’s investments). The allocation of expenses by the Adviser between it and a Client and among Clients represents a conflict of interest for the Adviser. The Adviser has adopted an expense allocation policy that is designed to address this conflict. The Adviser allocates expenses to each Client in accordance with the Client’s Governing Documents. The Adviser will seek to allocate any shared expenses for products and services benefitting multiple Clients or both the Adviser and a Client and not covered in the Client’s Governing Documents, in a fair and reasonable manner. Clients incur brokerage and other transaction costs. Please see Item 12, “Brokerage Practices” below for a discussion of certain brokerage expenses. The Adviser has no affiliated broker-dealers. |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
Item 7. Types of Clients The Clients consist of pooled investment vehicles. Any initial and additional subscription minimums with respect to investment in a Client are disclosed in the Governing Documents for each Client. |
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Praxis Precision Medicines Inc | 10.6 | ||
| Minerva Neurosciences Inc | 10.0 | ||
| OVID Therapeutics Inc | 6.3 | ||
| Compass Pathways PLC | 5.8 | ||
| Tarsus Pharmaceuticals Inc | 5.7 | ||
| Solid Biosciences Inc | 5.5 | ||
| Olivia Ventures Inc | 5.3 | ||
| Promis Neurosciences Inc | 5.3 | ||
| Edgewise Therapeutics Inc | 5.1 | ||
| Uniqure NV | 4.9 | ||
| View All | |||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | Ally Bridge Medalpha International Fund Limited | [2021-06-30] | 5.0 M | 118.2 M |
| Filed 2025-11-14 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Ally Bridge Medalpha US Fund LP | [2021-06-30] | 14.0 M | 3.5 M |
| Filed 2025-11-14 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Ally Bridge Medalpha Master Fund LP | [2019-03-28] | 5.0 M | 218.9 M |
| Filed 2025-11-14 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 3 | 218.9 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 3 | 218.9 |
| By Discretionary | ||
| Discretionary | 3 | 218.9 |
| Non-Discretionary | 0 | 0.0 |
| Total | 3 | 218.9 |
| By Non-United States Persons | ||
| Non-United States Persons | 211.7 | |
| United States Persons | 7.2 | |
| Total | 3 | 218.9 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Martin Laufer | Director | 69 | 13 | |
| Christopher Lebeau | Director | 34 | 13 | |
| Jarard Blake | Director | 16 | 7 | |
| Fan Yu | Director | 27 | 4 | |
| Vimbai Gurure | Director | 4 | 4 | |
| Anna Yaeger | Director | 3 | 3 | |
| Robert Castrignano | Director | 4 | 2 | |
| Simos Simeonidis | Director | 3 | 2 | |
| Jian Xiao | Director | 2 | 2 | |
| Ally Bridge Group HK Limited | Executive Officer | 2 | 1 | |
| Ally Bridge Group Ny LLC | Executive Officer | 2 | 1 | |
| Ally Bridge Medalpha Managment LP | Executive Officer | 1 | 1 | |
| Ally Bridge Medalpha Management LP | Executive Officer | 1 | 1 | |
| Ally Bridge Medalpha General Partner LP | Executive Officer | 1 | 1 | |
| Slanix Alex | Director | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001822947] | |
| 3 | [0001822947] | |
| 4 | [0001822947] | |
| SC 13G | [0001822947] |
| Form 13D/13G Filer | Form 13D/13G Subject | Filed |
|---|---|---|
| Ally Bridge Group NY LLC | Cogent Biosciences Inc | [2020-11-19] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $0.5B |
| Clients | 3 (67 non-US) |
| Serves | Institutional |
| Fund Types | Hedge Fund |
| LEI | 549300OLTAFEOY6ZKY22 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Amorfix Life Sciences Ltd PMN
Common Shares
|
2026-02-03 | Buy | 700,741 | $12.13 | 8,499,988 |
|
Amorfix Life Sciences Ltd PMN
Warrants · derivative
|
2026-02-03 | Buy | 700,741 | ||
|
Amorfix Life Sciences Ltd PMN
Option (right to buy) · derivative
|
2025-10-22 | Grant | 40,000 | $0.00 | |
|
MYOS RENS Technology Inc MDVL
Series A Warrant (Right to Buy) · derivative
|
2023-06-16 | Other | 965,130 | ||
|
MYOS RENS Technology Inc MDVL
Series A Warrant (Right to Buy) · derivative
|
2023-06-16 | Other | 6,818,181 | ||
|
MYOS RENS Technology Inc MDVL
Pre-Funded Warrant (Right to Buy) · derivative
|
2023-03-13 | Buy | 6,818,181 | $0.32 | 2,181,818 |
|
MYOS RENS Technology Inc MDVL
Pre-Funded Warrant (Right to Buy) · derivative
|
2023-03-13 | Buy | 965,130 | $0.32 | 308,842 |
|
MYOS RENS Technology Inc MDVL
Common Stock
|
2022-04-04 | Buy | 2,974,117 | $1.06 | 3,152,564 |
|
MYOS RENS Technology Inc MDVL
Warrant (Right to Buy) · derivative
|
2022-04-04 | Buy | 5,571,764 | $1.06 | 5,906,070 |
|
MYOS RENS Technology Inc MDVL
Warrant (Right to Buy) · derivative
|
2022-04-04 | Buy | 1,487,058 | $1.06 | 1,576,281 |
|
MYOS RENS Technology Inc MDVL
Common Stock
|
2022-04-04 | Buy | 11,143,529 | $1.06 | 11,812,141 |
|
MYOS RENS Technology Inc MDVL
Common Stock
|
2020-12-31 | Buy | 6,943 | $15.00 | 104,145 |
|
MYOS RENS Technology Inc MDVL
Common Stock
|
2020-12-31 | Buy | 5,727 | $15.00 | 85,905 |
|
MYOS RENS Technology Inc MDVL
Common Stock
|
2020-12-29 | Buy | 45 | $14.00 | 630 |
|
MYOS RENS Technology Inc MDVL
Common Stock
|
2020-12-29 | Buy | 55 | $14.00 | 770 |
|
MYOS RENS Technology Inc MDVL
Common Stock
|
2020-12-28 | Buy | 3,894 | $13.98 | 54,438 |
|
MYOS RENS Technology Inc MDVL
Common Stock
|
2020-12-28 | Buy | 3,213 | $13.98 | 44,918 |
|
MYOS RENS Technology Inc MDVL
Common Stock
|
2020-12-24 | Buy | 4,019 | $13.99 | 56,226 |
|
MYOS RENS Technology Inc MDVL
Common Stock
|
2020-12-24 | Buy | 4,871 | $13.99 | 68,145 |
|
MYOS RENS Technology Inc MDVL
Common Stock
|
2020-12-23 | Buy | 9,810 | $13.99 | 137,242 |
| showing 20 of 39 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Octagon Asset Management LLC
✚
|
NC | 221.2 M |
|
Triavera Capital LLC
✚
|
CA | 220.6 M |
|
Incision Capital Management LP
✚
|
CA | 220.3 M |
|
Sunstone Asset Management LP
✚
|
NY | 220.2 M |
|
Tolis Advisors LP
✚
|
NY | 219.6 M |
|
Ripple Effect Asset Management LP
✚
|
NY | 218.4 M |
|
Butler Hall Capital LLC
✚
|
CA | 218.3 M |
|
Jackson Hill Advisors LLC
✚
|
TX | 217.9 M |
|
Oppvest LLC
✚
|
NY | 217.8 M |
|
Mara River Capital Management LP
✚
|
FL | 217.7 M |